Commercial strategy, Ops guidance, Fundraising, Marketing etc.

COPD/respiratory focused AI based device/remote patient monitoring to drive compliance thus reducing unnecessary ER visits, 30 re-admit penalties, private payor costs, etc.Accomplishments:2023: Recruited Chair of MAB who recruited top KOLs to establish first US MAB 2023: Authored Private pay “Risk share” program 2022: Recruited US based Biz Dev professional fostering new large-scale opportunities

Provided oversight, commercial expertise/support, operations and corp governance.

Appointed CEO at a critical juncture. Avertix is global cardiology company with distribution agreements in Australia, Singapore, Japan and others, Avertix developed The Guardian as the world’s First and Only FDA-Approved Class III implantable cardiac device which 24/7 monitors, detects in real-time, then alerts patient of silent or atypical symptomatic heart attacks with actional data. Additionally, The Guardian, detects Afib, Tachy, Brady abnormalities, thus a RPM strategy and data value creation.Accomplishments:2023-led total re-brand/creation of Co & product marketing, collaterals, and website <60 days2023-Led strategy & Investor relations in anticipation to IPO (Creative narrative/Press releases etc.)2022-Authored commercial strategy, compensation plan and focused metrics2022-Replaced Market Access group, rewrote strategy and hired new team2022-Concepted CRPM and data “value proposition” estimated $3B market opportunity2021-Hired CCO, procured Salesforce and set up Customer Service2021-Received FDA Approval June 20212021-Authored, executed 90 day “survive to strive” plan2021-Reduced burn rate ~25% <30 days of start2021-Immediately $6MM in (< 30 days) to survive and execute on “stop gap” plan2021-Company reset (right sized employee base initial 30-60 days) representing 25% of employees2021-Awarded TPT code: GUARDIAN, 2nd only diagnostic to receive code: $10,250 ASP2021-Established systems, process, and protocols to prepare for commercial stage2021-Hired 3 Sales Professionals for limited reconnaissance commercial launch

Appointed CEO role from Director during pandemic and major capital constraints.Sonablate is a Global entity commercialized in >25 countries, including US and Mexico. The minimally invasive PMA approved HIFU prostate disease company had >57 employees/vast distribution network direct US commercial and in-house Mfg.,Accomplishments:2021-Raised $20MM leading to an exit with a PE firm.2021-Negotiated $50MM 3 yr. OUS Sales distribution commitment for Asian2021-Negotiated debt holders to exit with 3 firms representing ~$18MM 2021-Implemented “best practices” focused on operations, streamlining Mfg. & R&D2020-Executed comprehensive global commercial review/analytics/strategy review resulting infirst ever co price increase for capital equipment and disposables2020-Executued <27% overall COGS reduction

Stealth (AI) Artificial Intelligence Healthcare IT company focused on disrupting traditional Rep to HCP marketing/education, physical in-office sampling, inventory management/reconciliation, and analytics powered by SampleScribe proprietary cloud-based algorithm.Duties: Executive Summary, patent, Investor deck/s, funding, IP strategy, operations infrastructure (compliance, regulatory, etc), commercial roll-out (sales/marketing) and process flow.2019-Architecture/Core Functionionality complete2018-Filed Non-Provisional2018-Full Mark Analysis and Strategy complete

Expertise in developing executive summary, Investor deck/s, funding, IP strategy, operations infrastructure (compliance, regulatory, clinical, HR, legal, IT, etc.). Full market analysis, pre/post commercial roll-outs (sales/marketing/operations), process improvement, requirements, pricing modeling, budgets, forecasting, patent strategy, funding, scaling, turnarounds and execution.

BTGplc (BSC acquired $4.2B) 2/2013-8/2017 Vice President Sales and MarketingLed 3/4 D leading Sales, Marketing, Commercial Ops. Lead VPS 2- NSMs, 7 RSMs & 100+ Commercial Pros with combined >$500MM revs. Member of leadership integrally involved in Compliance, Legal, Quality, Finance, Market Access, Ops, Mfg. and M&A. Interventional Pulmonology 3/2016-8/2017Disruptive technology leading OUS Marketing/US strategy. Streamlined OUS/US process, and drove EU sales efforts.2016-US overhaul of Marketing team for “fit for purpose.” 2016-Complete rebrand of product and company (logo/tag/colors/website etc.)2016-Implemented BI, analytics, CRM: Salesforce & Tableau.2016-Created and implemented digital awareness campaigns to HCPs and referring HCPs2016-Established systems/processes to execute plans as one working document Specialty Biotech 3/2015-5/2016Recruited for “turn-around” declining revenue Div. Led 2-NSMs 14-Sales Pros with ~$240MM in revs selling antidotes in specialty call points: Oncology, ER, & Hematology.2015-Created new Oncology division: NSM/ 8 Sales Professionals/MSLs2015-<9 months drove revenues +$4MM from baseline.2015-Revamped sales force, compensation plan, incentives, metrics tracking and hiring process2015-Led revamped ground floor Marketing plans from Sales Rep to pilot to implementation critical resources/programs.Interventional Oncology 2/2013-5/20152014-25% YoY growth2014-37% product growth from flagship acquisition2013-Doubled Sales Management, tripled Sales Team, pilot Therapy awareness program 2013 3%+ ASP growth and drove existing business 15%2012-Revamped Commercial team: Sales/Sales Management resulting in 30% "reset"2012-Co lead integration of $200MM acquisition2012-Led commercial overhaul down to objection handling, talk track to strategy/resources

Authored commercial launch, talk track, messaging, call targets, call points, compensation plans/transfer rates.

Developed full commercial planning, budgets, strategy, business development, funding strategy, product development, IP, 510K approved

VC funded vessel sealing technology calling on Robotics, Bariatric, General, Colon & Rectal, Gyn/Surgical Oncology. Lead team of Director of Sales, 7 Sales Pros, 5 Dist and Customer Service including P&L, reRep2009/2010-metrics: 86% account re-peat usage, $687 ASP (40% higher than competitor), opened 36 accounts from 02009/2010-launched 3 products for “open” and “laparoscopic” procedures2009-Lead brand identity and marketing materials for company and products

Unique Endoscopic device focusing on tissue acquisition and Endoscopic stabilizer system. Company was founded by Interventional Pulmonologist Dr William Krimsky, VP of Engineering and self.2008-Recruited VP of R&D and Finance leadership2008-Devised Corp governance, corporate strategy, market assessment, investor deck, executive Summary, patent strategy, Patent Issued: PCT/US200904437

A VC funded 2nd generation Drug Eluting and Bare Metal Coronary Stent, PTCA and additional Cardiology platform. Managed a Country manager (GmBh) and signed EU 2 distributors. 2007 Developed OUS market strategy for CE commercial launch and EU market analysis2007 Developed and Implemented Customer Service systems and processes, and branding

VC funded Women’s healthcare company focused on a “percutaneous lesion removal” and tissue acquisition devices. Call points include Surgeons and Interventional Radiologists. Lead 2 Region Managers and 8 Sales Professionals. Reported to CEO.2006 Member of 3 person Executive Team that raised over $25MM in capital2006 Hired and lead strategy from zero revenues.

Lead 8 Region Mgrs and 65 Sales Professionals. Directly hired 25+ Sales Professionals. Revenues exceeded $40MM. Launched 5 new devices for peripheral/coronary disease. Nationally lead all reimbursement and value proposition training US team. Negotiated IDN and Hospital contract. 2005:Revs:$128MM>Sales Team: 204 Sales Professionals\27 Region Mgrs\4 Area Directors2004:Revs:$38.5MM> Sales Team: 115 Sales Professionals\13 Region Mgrs\2 Area Directors2003 Revs:$2.1MM> Sales Team:12 Sales Professionals\2 Region Mgrs.Average Selling Price: Q3 2003 $1495; Q4 2004: $2099; Q4 2005: $2650 Valuation: July 2003 $20M; October 2004 (IPO) $320M; Dec 2005 $1.1B